Navigation Links
MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions

CHICAGO, June 21, 2007 /PRNewswire/ --

What and When

Data from the PROactive and CHICAGO studies of ACTOS(R) (pioglitazone HCl) will be presented in poster format at the 67th Scientific Sessions of the American Diabetes Association in Chicago:

    -- Hospitalizations for serious adverse events in high-risk type 2

       diabetes patients treated with pioglitazone for 3 years: results from

       PROactive; Poster 0553-P presented on Saturday, June 23, from 12:30-

       2:30 p.m. and 6:00-7:15 p.m.

    -- The relationship between renal dysfunction and major cardiovascular

       outcomes in patients with diabetes: experience from PROactive; Poster

       0670-P presented on Saturday, June 23, from 12:30-2:30 p.m. and 6:00-

       7:15 p.m.

    -- Effects of pioglitazone in patients with type 2 diabetes and reduced

       glomerular filtration rate: an analysis from PROactive; Poster 0671-P

       presented on Saturday, June 23, from 12:30-2:30 p.m. and 6:00-7:15 p.m.

    -- Effects of long-term treatment with pioglitazone on lipid levels in

       patients receiving statin therapy at baseline in the PROactive study;

       Poster 0905-P presented on Sunday, June 24, from 12-2 p.m. and 6:15-

       7:30 p.m.

    -- Comparative effects of pioglitazone and glimepiride on lipoprotein

       subfractions: results from the CHICAGO Trial; Poster 0906-P presented

       on Sunday, June 24, from 12-2 p.m. and 6:15-7:30 p.m.

    -- Long-term cost-effectiveness analysis on ACTOS for the USA from

       PROactive; Poster 1209-P presented on Sunday, June 24, from 12-2 p.m.

       and 6:15-7:30 p.m.

About ACTOS

ACTOS works by directly targeting insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ACTOS is taken once daily as an adjunct to diet and exercise, and is approved for use for t
'"/>




Page: 1 2 3

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
3. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
4. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
10. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
(Date:1/6/2009)...E, Md., Jan. 6 Sequella... focused on diseases of epidemic potential, announ...the treatment of tuberculosis (TB), was the first ...inical program contract to Dynport Vaccine Company...arded by the National Institute of Allergy and Inf...
(Date:1/5/2009)...ESDA, Md., Jan. 5 Microm...ompany developing novel, proprietary,antibodies f...mmune diseases,provides an outlook on key events...t intends to provide an update on its research and..., -- April 12 to 16, 2009: Update on several ...
(Date:12/27/2008)...D,S, Bermuda, Dec. 23 Wa...today that one of its subsidiaries and Mayne Pharm...of Hospira, Inc., have filed lawsuits against each..., Mylan Pharmaceuticals Inc. ("Mylan") and Impax L... for the District of New Jersey for infringement o...
(Date:12/17/2008)...est, Most Complex of Its Kind; 80 Percent of Traum..., Dec. 17 A multi-disciplinary tea...ntly performed the first near-total face transpla...procedure performed within the past two weeks, sur...o suffered severe facial trauma -- essentially rep...
Breaking Medicine Technology:Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 3Six Positive Predictions for 2008 from SuperLife World Service 8518 1Six Positive Predictions for 2008 from SuperLife World Service 8518 2ethiKids inc Launches Website and Products to Address Declining Ethics in Children 8516 1ethiKids inc Launches Website and Products to Address Declining Ethics in Children 8516 2China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 8514 1China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 8514 2AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 1AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 2
...ce suggests that if you,could choose your parents,...ase. Researchers from the long-standing,Framingham...t,Lung, and Blood Institute (NHLBI) of the Nation...parents live longer were more,likely to avoid deve...other risk factors for cardiovascular disease in m...
...3, 2007 -,Cytos Biotechnology AG (SWX:CYTN) report...ith CYT003-QbG10, an immunotherapeutic,product can... study,included 40 patients suffering from mild to...lergy (hay fever). The trial,investigated in a dou...oratory efficacy of two different formulations of ...
Other Medicine Technology:Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 2Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7
(Date:1/8/2009)...e introduces Senator Daschle at his confirmation h...n Services , , , WASHINGTON, Jan. 8 /PRNewswi...ounding board member Senator Tom Daschle, nominee ...ary, was introduced by fellow BPC founder and frie...day. The hearing was convened by the Senate Health...
(Date:1/8/2009)...pts Prenatal Solution Key Factor in Decision for F...RLANDO, Fla., Jan. 8 All...LLC, one of the largest multi-specialty group prac... the Allscripts Enterprise(TM) Electronic Health R...cians in 18 offices across Central Florida. , ...
(Date:1/8/2009)...lowered bad cholesterol more effectively than Zoco...-- After nearly a year of review, U.S. health offi...ued use of the controversial cholesterol-lowering ...ration said there was no significant difference in...Vytorin and patients taking the drug Zocor. , B...
(Date:1/8/2009)... local dance students will dance to raise money fo...IS, Jan. 8 , , , WHO: ...show off their talent in the 3rd annual Dance, ...ance Arts Centre. The, event will..., Participants raise money throu...
Breaking Medicine News(10 mins):Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Dance With Courage to Benefit Camp Courage 2
...a steroid nasal spray to quash allergy symptoms ma...s say that when used on an "as-needed'', rather th...se) relieves// allergy symptoms such as runny nose...vely than the antihistamine loratadine (Claritin)....
...on of intravenous magnesium sulfate to standard em...amide, appears to reduce rather than enhance the e...olleagues from the Albert Einstein College of Medi...vidence that magnesium may be helpful in the treat...
...who smoke during pregnancy are more likely to bear...higher risk than others because of genetic suscept...determine the causes of low birth weight, though t...mmending at this point that women be screened for ...
... of Swiss researchers found that butterbur extract...fects. Mr John de Carpentier said,presumably it co... would not work - and therefore it is possible tha...ons. It was used in treating hayfever The researc...
Other Medicine News:
Aluminum Stylette 16 with Adjustable Stop.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Aluminum Stylette 16.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Medicine Products: